SYM FINANCIAL Corp Invests $218,000 in Zoetis Inc. (NYSE:ZTS)

SYM FINANCIAL Corp bought a new stake in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,107 shares of the company’s stock, valued at approximately $218,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. FinTrust Capital Advisors LLC boosted its position in Zoetis by 42.1% in the third quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock valued at $45,000 after buying an additional 77 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Zoetis by 6.3% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 165,588 shares of the company’s stock valued at $28,809,000 after acquiring an additional 9,757 shares during the last quarter. Stratos Wealth Advisors LLC acquired a new stake in shares of Zoetis in the third quarter worth $209,000. Independent Advisor Alliance raised its holdings in shares of Zoetis by 9.3% during the third quarter. Independent Advisor Alliance now owns 2,509 shares of the company’s stock worth $437,000 after purchasing an additional 213 shares during the last quarter. Finally, Groesbeck Investment Management Corp NJ lifted its position in Zoetis by 8.2% during the third quarter. Groesbeck Investment Management Corp NJ now owns 3,300 shares of the company’s stock valued at $574,000 after purchasing an additional 250 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS traded down $0.16 on Friday, hitting $167.07. The company had a trading volume of 3,007,125 shares, compared to its average volume of 4,607,073. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The company has a market capitalization of $76.41 billion, a PE ratio of 32.19, a PEG ratio of 2.62 and a beta of 0.86. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company’s fifty day moving average price is $168.88 and its 200-day moving average price is $178.84.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.74%. The firm had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter in the prior year, the firm earned $1.31 EPS. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. As a group, analysts predict that Zoetis Inc. will post 5.78 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio is presently 33.33%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the sale, the executive vice president now owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 2,209 shares of company stock worth $371,293. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Stifel Nicolaus decreased their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday. The Goldman Sachs Group upped their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Barclays cut their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 23rd. Finally, StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average target price of $216.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.